LEXAPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6916941 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
| US7420069 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
|
US7420069 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) | |
|
US6916941 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) | |
Lexapro is owned by Abbvie.
Lexapro contains Escitalopram Oxalate.
Lexapro has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Lexapro are:
- US6916941
- US7420069
- US7420069*PED
- US6916941*PED
Lexapro was authorised for market use on 14 August, 2002.
Lexapro is available in tablet;oral dosage forms.
The generics of Lexapro are possible to be released after 12 May, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 12, 2026 |
Drugs and Companies using
ESCITALOPRAM OXALATE ingredient
Market Authorisation Date:
14 August, 2002Treatment:
NADosage:
TABLET;ORAL
How can I launch a generic of LEXAPRO before its drug patent expiration?
More Information on Dosage
LEXAPRO family patents
